Phillip M. Satow Resigns from Forest Laboratories Board of Directors
July 01 2005 - 9:05AM
PR Newswire (US)
Phillip M. Satow Resigns from Forest Laboratories Board of
Directors NEW YORK, July 1 /PRNewswire-FirstCall/ -- Forest
Laboratories, Inc. (NYSE:FRX) today announced that Phillip M.
Satow, a member of the Company's Board of Directors and former
Executive Vice President of the Company, has resigned from the
Board of Directors. Mr. Satow, who serves as the Chairman and Chief
Executive Officer of JDS Pharmaceuticals, LLC, a privately-held
pharmaceutical company, indicated that he was reluctantly resigning
from Forest, with which he has been happily associated for more
than 20 years, to avoid any potential conflict of interest between
the business of JDS as it may develop in the future and his Board
service for Forest. Although Mr. Satow thought it advisable to step
aside from his Board membership, he indicated that he would remain
available to provide advice and guidance to the Company. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO) Howard
Solomon, Forest's Chairman and Chief Executive Officer stated: "All
of us at Forest greatly appreciate the creativity and talent Phil
brought to Forest during his many years as an executive officer, as
well as during his years as a non-employee member of our Board.
Phil was a leading force in the development and expansion of
Forest's sales and marketing capabilities, including the
extraordinary launch of Celexa and Forest's antidepressant
franchise. His knowledge of our industry, expertise and personal
warmth and integrity made him an invaluable member of our Board."
Following Mr. Satow's resignation, the Forest Board is now
comprised of six members, four of whom are classified as
independent in accordance with New York Stock Exchange criteria.
Forest intends to seek an additional independent member of the
Board of Directors during the course of the current fiscal year.
Except for the historical information contained herein, this
release contains "forward-looking statements" within the meaning of
the Private Securities Reform Act of 1995. These statements are
subject to risks and uncertainties that affect our business,
including risk factors listed from time to time in the Company's
SEC reports, including the Company's Annual Report on Form 10-K for
the fiscal year ended March 31, 2005.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE:
Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice
President-Investor Relations of Forest Laboratories, Inc.,
+1-212-224-6714 Web site: http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024